Nuvectis Pharma Inc (NVCT) Stock Price, Quote & News

Company Profile

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits th...

Industry: Biotechnology

Sector: Healthcare

Phone: 201 614 3150

Website: www.nuvectis.com

Address:

1 Bridge Plaza, Suite 275, Fort Lee, United States

cupcakes4jesus Jun. 16 at 6:49 PM

$NVCT going back to $5-6 on nxp800 data

0 · Reply

CastielHuangi Jun. 16 at 3:56 PM

$NVCT

0 · Reply

BioSensai Jun. 16 at 2:55 PM

$NVCT Data likely this month aka this week or next. farthest out will be first week of July. Tons of news coming with commencement of 1b for -900 and, if positive, start of 2b for NXP-800

0 · Reply

BioSensai Jun. 16 at 2:27 PM

$NVCT Calling that the bottom. -800 data out in the next 30 days, likely this week or next all eyes on NXP-900

0 · Reply

BioSensai Jun. 16 at 1:51 PM

$NVCT 1b for NXP-800 out within the next 30 days. At this price not sure there is any downside

0 · Reply

BioTrade2 Jun. 16 at 12:55 PM

$NVCT “throbocytopenia isn’t dose dependent, it’s time dependent”. What!?!?

1 · Reply

cupcakes4jesus Jun. 16 at 4:51 AM

$NVCT on our way back to $6 as I have said in the past

1 · Reply

BioTrade2 Jun. 15 at 2:22 AM

$NVCT $NVCT if they saw these many stable diseases with tumor shrinkage, you have to think 75mg bodes well. I think we get decent number of PRs in the 75mg cohort, safety is the biggest question

0 · Reply

cupcakes4jesus Jun. 13 at 4:05 PM

$NVCT all this for it to go back to $5 on the nxp800 update which will come before nxp900 1b initiation

1 · Reply

BioTrade2 Jun. 13 at 4:03 PM

$NVCT from today’s corporate presentation update

0 · Reply

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

May 6, 2025, 8:00 AM EDT - 5 weeks ago

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

Apr 29, 2025, 4:25 PM EDT - 6 weeks ago

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

Mar 14, 2025, 8:00 AM EDT - 3 months ago

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

Feb 7, 2025, 8:30 AM EST - 4 months ago

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option

Feb 6, 2025, 2:00 PM EST - 4 months ago

Nuvectis: Additional Data In Q2 Of 2025 Could Allow It To Stage A Comeback

Feb 5, 2025, 9:01 AM EST - 4 months ago

Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

Feb 4, 2025, 4:05 PM EST - 4 months ago

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

Nov 14, 2024, 2:23 PM EST - 7 months ago

Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug

Nov 5, 2024, 7:00 AM EST - 7 months ago

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

Oct 28, 2024, 8:21 AM EDT - 8 months ago

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

DRUG

Aug 29, 2024, 8:00 AM EDT - 10 months ago

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Aug 6, 2024, 8:28 AM EDT - 11 months ago

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights

May 16, 2024, 8:30 AM EDT - 1 year ago

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights

Apr 8, 2024, 8:30 AM EDT - 1 year ago

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines

Mar 19, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma to Present at the 36th Annual Roth Conference

Mar 14, 2024, 9:00 AM EDT - 1 year ago

Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Mar 5, 2024, 8:00 AM EST - 1 year ago

Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights

Feb 9, 2024, 8:32 AM EST - 1 year ago

Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Feb 9, 2024, 8:00 AM EST - 1 year ago

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Jan 3, 2024, 8:00 AM EST - 1 year ago

Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 8, 2023, 8:00 AM EST - 1 year ago

Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

Sep 25, 2023, 7:30 PM EDT - 1 year ago

Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation

Sep 21, 2023, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900

Sep 6, 2023, 8:03 AM EDT - 1 year ago

Nuvectis: Early Stage Company That's Low On Cash

Sep 6, 2023, 8:00 AM EDT - 1 year ago

Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900

Aug 17, 2023, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma

Aug 9, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights

May 15, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces FDA Clearance of NXP900 IND

May 10, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights

Apr 27, 2023, 10:14 AM EDT - 2 years ago

Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

Apr 10, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma

Mar 17, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting

Mar 10, 2023, 8:00 AM EST - 2 years ago

Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference

Mar 7, 2023, 8:00 AM EST - 2 years ago

Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights

Dec 1, 2022, 8:00 AM EST - 2 years ago

FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma

Nov 8, 2022, 8:00 AM EST - 2 years ago

Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights

Oct 18, 2022, 8:00 AM EDT - 2 years ago

Nuvectis Phrama Announces Two Upcoming Poster Presentations at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 3, 2022, 4:30 PM EDT - 2 years ago

Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference

Sep 28, 2022, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Formation of a Scientific Advisory Board

Sep 13, 2022, 8:30 AM EDT - 2 years ago

Nuvectis Pharma Announces Positive Data for NXP800 in a Preclinical Model of ARID1a-Mutated Gastric Carcinoma

Sep 7, 2022, 8:30 AM EDT - 3 years ago

Nuvectis Pharma, Inc. to Present at Upcoming Investment Conferences

Aug 5, 2022, 8:00 AM EDT - 3 years ago

Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights

Aug 1, 2022, 8:30 AM EDT - 3 years ago

Nuvectis Pharma Announces Closing of Approximately $15.9 Million Private Placement

Jun 21, 2022, 8:15 AM EDT - 3 years ago

Nuvectis Pharma Announces FDA Clearance of IND for NXP800

Jun 13, 2022, 8:30 AM EDT - 3 years ago

Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, A Type of Brain Cancer That Affects Predominantly Pediatric Patients

cupcakes4jesus Jun. 16 at 6:49 PM

$NVCT going back to $5-6 on nxp800 data

0 · Reply

CastielHuangi Jun. 16 at 3:56 PM

$NVCT

0 · Reply

BioSensai Jun. 16 at 2:55 PM

$NVCT Data likely this month aka this week or next. farthest out will be first week of July. Tons of news coming with commencement of 1b for -900 and, if positive, start of 2b for NXP-800

0 · Reply

BioSensai Jun. 16 at 2:27 PM

$NVCT Calling that the bottom. -800 data out in the next 30 days, likely this week or next all eyes on NXP-900

0 · Reply

BioSensai Jun. 16 at 1:51 PM

$NVCT 1b for NXP-800 out within the next 30 days. At this price not sure there is any downside

0 · Reply

BioTrade2 Jun. 16 at 12:55 PM

$NVCT “throbocytopenia isn’t dose dependent, it’s time dependent”. What!?!?

1 · Reply

cupcakes4jesus Jun. 16 at 4:51 AM

$NVCT on our way back to $6 as I have said in the past

1 · Reply

BioTrade2 Jun. 15 at 2:22 AM

$NVCT $NVCT if they saw these many stable diseases with tumor shrinkage, you have to think 75mg bodes well. I think we get decent number of PRs in the 75mg cohort, safety is the biggest question

0 · Reply

cupcakes4jesus Jun. 13 at 4:05 PM

$NVCT all this for it to go back to $5 on the nxp800 update which will come before nxp900 1b initiation

1 · Reply

BioTrade2 Jun. 13 at 4:03 PM

$NVCT from today’s corporate presentation update

0 · Reply

cupcakes4jesus Jun. 13 at 3:32 PM

$NVCT getting crushed back to $5

0 · Reply

cupcakes4jesus Jun. 13 at 12:03 AM

$NVCT you are fluent in Yapanese. Go get a grip choir boy 🧚

0 · Reply

cupcakes4jesus Jun. 13 at 12:02 AM

$NVCT stop yapping already choir boy 💅🏻

0 · Reply

BioSensai Jun. 12 at 6:44 PM

$NVCT Also - Clinicaltrial.gov shows NXP-800 1b in recruiting phase. if safety issue came up the trial would not be still recruiting. predicting big upside surprise in the next 2-3 weeks for -800. Even 33% PR would be a huge win

0 · Reply

BioSensai Jun. 12 at 6:42 PM

$NVCT Phase 1a for NXP-800 showed minimum dose required for efficacy was 50mg daily. It really should have not been a surprise that efficacy was not pronounced in 1b with 50mg intermittent, although it did show good control of thrombo. 75mg intermittent will likely land at same efficacy as 50mg DAILY, which should drive PR's while giving time for platelets to recover thus controlling thrombo issue. Insider buying. @cupcakes4jesus you still need to respond to why Charles decided to buy $400K worth BEFORE NXP-800 data and not after

0 · Reply

BioSensai Jun. 12 at 5:01 PM

$NVCT Insiders sell for many reasons, but only buy for one reason. Recent insider buying is indicative of GOOD results. Charles would have waited if he thought -800 would be bad, as clearly stock would take a hit. He clearly believes stock will be higher in future than today. -800 results in next few weeks

0 · Reply

BioSensai Jun. 12 at 2:55 PM

$NVCT watch NXP-800 be good and this thing flies

0 · Reply

cupcakes4jesus Jun. 11 at 7:10 PM

@BioTrade2 my understanding was that nxp800 was coming first, and based off their body language, and hardly discussing nxp800 in their press conference, I didn’t feel optimistic the data were looking good at that point in time. Everyone has their own way to skin the cat, but I think $5-6 is possible in the short term, but long term the value is incredible $NVCT

1 · Reply

cupcakes4jesus Jun. 11 at 4:06 PM

$NVCT if the nxp800 data were so great, why aren’t they releasing the data right now? There’s another side to that coin Timothy

1 · Reply

cupcakes4jesus Jun. 11 at 3:51 PM

$NVCT $ is starting to move into $CLBR 💰

0 · Reply

BioSensai Jun. 11 at 3:43 PM

$NVCT Two possible indicators for positive NXP-800 results: 1: $500K in insider buys by Charles, who is major shareholder and close friend with CEO 2: lack of news - If no responses seen, likely would cut study short and release news.

0 · Reply

BioSensai Jun. 11 at 3:02 PM

$NVCT Yet another higher low. Upside surprise could be huge here with positive NXP-800 results in next 2-3 weeks

0 · Reply

Market Cap	175.72M
Revenue (ttm)	0.00
Net Income (ttm)	-19.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	79,296
Avg Vol	133,248
Day's Range	N/A - N/A
Shares Out	20.89M
Stochastic %K	1%
Beta	-0.16
Analysts	Strong Sell
Price Target	$19.25